Quick Answer
KalVista Pharmaceuticals, Inc. reported Stockholders Equity of $95.39 million for fiscal year 2025.
KalVista Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $95.39M | -53.8% |
| 2024 | $206.58M | +28.3% |
| 2023 | $161.03M | -13.0% |
| 2022 | $185.09M | -28.0% |
| 2021 | $257.19M | +207.1% |
| 2020 | $83.75M | -13.4% |
| 2019 | $96.74M | +255.0% |
| 2018 | $27.25M | -13.0% |
| 2017 | $31.33M | +184.4% |
| 2016 | -$37.11M | -175.3% |
| 2015 | $49.31M | +309.3% |
| 2015 | -$23.55M | +46.7% |
| 2014 | -$44.18M | -172.6% |
| 2014 | -$16.21M | +51.9% |
| 2013 | -$33.71M | -19.2% |
| 2012 | -$28.29M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.00M | -88.6% | -58.3% |
| July 31, 2025 | $40.79M | -76.4% | -31.4% |
| June 30, 2025 | $59.45M | -67.1% | -37.7% |
| April 30, 2025 | $95.39M | -53.8% | -18.3% |
| March 31, 2025 | $116.76M | — | -19.5% |
| January 31, 2025 | $145.13M | — | -11.7% |
| December 31, 2024 | $164.36M | — | +22.7% |
| October 31, 2024 | $133.99M | — | -9.8% |
- KalVista Pharmaceuticals, Inc. showed a decrease of -53.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, KalVista Pharmaceuticals, Inc.’s stockholders equity has grown by 437.2% (from -$28.29 million to $95.39 million).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: